XOMA stock plunged after its partner Rezolute Inc. reported disappointing trial results for their product Ersodetug.

Rezolute still has another Phase III trial of ersodetug in progress to rely upon, with data expected in H2 2026.

Rezolute sinks after its Phase 3 congenital hyperinsulinism trial showed no statistically significant benefit for ersodetug despite favorable safety data.

A rare genetic disorder discovered by UT Southwestern Medical Center researchers and their colleagues can cause brain damage ...

Lakshith Guptha Nalla was just four weeks old when he died at the University Hospital of Wales in the early hours of May 11, ...

An investigation into the University Hospital of Wales in Cardiff has revealed shocking pictures of filthy hallways, ...

SERENA WILLIAMS showed off her incredible figure in a cut-out swimsuit. The tennis great, 44, dazzled on the front cover of ...

STEPPING onto her scales Rosie Parsons’ eyes widened in horror. It had been just 30 days since she had stopped taking the weight loss jab Ozempic but already her clothes had begun clinging.

Think about the last meal you enjoyed. You probably didn't consider whether it might kill you. Most of us trust that the food ...

Breastfeeding for the first six months provides complete nutrition, immunity, and hydration for the newborn. Colostrum ...

The number of babies hospitalized with infant botulism has increased. A total of 51 infants have now been hospitalized amid an outbreak of infant botulism, a type of severe illness caused by botulinum ...